Labtec GmbH's Sufentanil Patch for Chronic Pain Enters Phase II in Cooperation With Hameln Pharmaceuticals gmbh

Published: Nov 01, 2010

LANGENFELD/RHEINLAND, Germany--(BUSINESS WIRE)--Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

Back to news